Significant Accounting Policies (Details) - USD ($) |
12 Months Ended | |||
|---|---|---|---|---|
Dec. 31, 2021 |
Dec. 31, 2020 |
Dec. 31, 2019 |
Sep. 30, 2020 |
|
| Accounting Policies [Abstract] | ||||
| Research and development expenses | $ 28,000 | |||
| Considerations contingent | $ 14,000 | |||
| Termination provisions | 14,000 | |||
| Transaction price | 5,000,000 | |||
| Reimbursement cost | $ 1,000,000 | |||
| Option exercise | $ 3,000,000 | |||
| Income tax percentage | 50.00% | |||
| Warrants exercisable (in Shares) | 1,590,346 | 4,008,007 | 3,536,495 | |
| X | ||||||||||
- Definition Option exercise No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of liability recognized from contingent consideration in asset acquisition. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of other research and development expense. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Definite liabilities to third parties under a termination loan agreement, whether or not guaranteed in whole or in part by the government. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|